Compare BBY & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | NBIX |
|---|---|---|
| Founded | 1966 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2B | 15.5B |
| IPO Year | 1994 | 1996 |
| Metric | BBY | NBIX |
|---|---|---|
| Price | $101.23 | $164.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 25 | 29 |
| Target Price | $87.85 | ★ $207.50 |
| AVG Volume (30 Days) | ★ 2.8M | 1.4M |
| Earning Date | 11-24-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | 17.76 | ★ 41.95 |
| EPS | 2.79 | ★ 5.26 |
| Revenue | ★ $41,691,000,000.00 | $161,626,000.00 |
| Revenue This Year | $2.34 | $36.46 |
| Revenue Next Year | $1.67 | $17.43 |
| P/E Ratio | $36.33 | ★ $31.57 |
| Revenue Growth | 0.39 | ★ 977.51 |
| 52 Week Low | $55.10 | $122.14 |
| 52 Week High | $101.49 | $186.12 |
| Indicator | BBY | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 69.59 |
| Support Level | $59.52 | $152.67 |
| Resistance Level | N/A | $169.57 |
| Average True Range (ATR) | 3.54 | 4.61 |
| MACD | 0.27 | 2.82 |
| Stochastic Oscillator | 79.44 | 85.33 |
Best Buy Co Inc is a pure-play consumer electronics retailer in the USA. It has two reportable segments: Domestic and International. The Domestic and International segments have offerings in six revenue categories. Computing and Mobile Phones, Consumer Electronics, Appliances, Entertainment, Services, and Other. The company has approximately 1,068 stores throughout its Domestic and International segments. It also have vendor store-within-a-store concepts to allow closer vendor partnerships and a higher quality customer experience. The company generates majority of its revenue from the Domestic segment.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.